Adial Announces Appointment of Tony Goodman as Chief Operating Officer

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Tony Goodman as Chief Operating Officer.

A highly accomplished pharmaceutical industry executive and member of Adial’s Board of Directors since 2017, Mr. Goodman will oversee the Company’s strategic growth initiatives, including clinical development and commercial planning for AD04, as well as business development initiatives focused on partnership opportunities in the area of addiction treatment. He will continue to serve on Adial’s Board.

Cary J. Claiborne, Adial’s Chief Executive Officer, stated, “We welcome Tony to the senior management team at this pivotal time for the Company. He brings senior leadership and business development experience from his past work with several pharmaceutical companies, including Indivior, where he and I worked closely together. The addition of Tony to the Adial team enables us to more fully benefit from his extensive experience and successful track record within the biopharmaceutical industry, especially within the addiction space, as we approach the next phase in our advancement of the AD04 clinical program and begin preparations for potential commercialization for the treatment of alcohol use disorder (“AUD”). We look forward to Tony executing in his new role as we move toward completion of our partnering activities and advance the AUD program into the next stage of clinical development.”

Mr. Goodman commented, “After supporting Cary and Adial with strategic partnering initiatives following the ONWARD™ trial, I strongly believe in the value that AD04 can bring to patients struggling with AUD. AD04 is a unique asset, and our post hoc analyses bring new hope that the next trials will prove the clinical relevance of AD04 in treating AUD. I look forward to leading the efforts to bring this much needed treatment to patients.”

Mr. Goodman’s career spans more than 23 years in the pharmaceutical and biotech industries. He is the founder and Managing Director of The Keswick Group LLC, a strategic commercial and business development advisory firm. From October 2014 until February 2017, he served as the Chief Business Development Officer of Indivior PLC (INDV, FTSE 500) and a member of the executive team that brought it public as a de-merger from Reckitt Benckiser Inc., the parent company of Reckitt Benckiser Pharmaceuticals (“RBP”). Mr. Goodman held many leadership positions at RBP and Indivior from 2006 until 2017 that included Global Director, Commercial Development and Strategic Planning; Global Head, Category Development; Director of US Business Development; and Director of US Commercial Managed Care. During his time at RBP, revenue grew to more than $1 billion annually in the addiction market. He has also served as the Director of Strategic Marketing and Business Development at PRA International. Mr. Goodman graduated from Marshall University with a degree in Business Administration and is currently a Full Board Executive with the National Association of Corporate Directors (“NACD”).

Learn more here.

Recent News


Protected: Don’t Miss These Spring Talent Events

There is no excerpt because this is a protected post.


SRI selected as spoke for both ARPA-H Customer Experience Hub and Investor Catalyst Hub

SRI has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to serve as a spoke within the Customer Experience Hub (CX Hub) and the Investor Catalyst Hub (IC Hub), as part of ARPANET-H, a nationwide health innovation network launched in September 2023. “Hundreds of organizations have been selected to join each network.


ReAlta Life Sciences Announces Dosing of First Patient in Phase 2 Trial of RLS-0071 for Acute Exacerbations of Chronic Obstructive Pulmonary Disease

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, announced enrollment of the first patient in a Phase 2 clinical trial evaluating the safety and efficacy of RLS-0071, an investigational new drug based on ReAlta’s novel EPICC peptide